RT Journal Article
SR Electronic
T1 Repeat COVID-19 Molecular Testing: Correlation with Recovery of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.05.20168963
DO 10.1101/2020.08.05.20168963
A1 Gniazdowski, Victoria
A1 Morris, C. Paul
A1 Wohl, Shirlee
A1 Mehoke, Thomas
A1 Ramakrishnan, Srividya
A1 Thielen, Peter
A1 Powell, Harrison
A1 Smith, Brendan
A1 Armstrong, Derek T.
A1 Herrera, Monica
A1 Reifsnyder, Carolyn
A1 Sevdali, Maria
A1 Carroll, Karen C.
A1 Pekosz, Andrew
A1 Mostafa, Heba H.
YR 2020
UL http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168963.abstract
AB Repeat molecular testing for SARS-CoV-2 may result in scenarios including multiple positive results, positive test results after negative tests, and repeated false negative results in symptomatic individuals. Consecutively collected specimens from a retrospective cohort of COVID-19 patients at the Johns Hopkins Hospital were assessed for RNA and infectious virus shedding. Whole genome sequencing confirmed the virus genotype in patients with prolonged viral RNA shedding and droplet digital PCR (ddPCR) was used to assess the rate of false negative standard of care PCR results. Recovery of infectious virus was associated with Ct values of 18.8 ± 3.4. Prolonged viral RNA shedding was associated with recovery of infectious virus in specimens collected up to 20 days after the first positive result in patients who were symptomatic at the time of specimen collection. The use of Ct values and clinical symptoms provides a more accurate assessment of the potential for infectious virus shedding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the department of pathology, Johns Hopkins School of Medicine, the NIH Johns Hopkins Center of Excellence in Influenza Research and Surveillance HHSN272201400007C (A.P., H.H.M.) and T32A1007417 Molecular and Cellular Basis of Infectious Diseases (H.P. and B.S.). No third party payments were received for the performance of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed in the Molecular Virology Laboratory, Johns Hopkins Hospital. Cell culture studies were conducted at the Johns Hopkins Bloomberg School of Public Health. The study was approved by the Johns Hopkins University School of Medicine Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesVirus sequence data has been submitted to public databases including GISAID and Genbank.